Acadia announces positive results of Phase 3 trial to treat psychosis
Category: #health  By Pankaj Singh  Date: 2019-12-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Acadia announces positive results of Phase 3 trial to treat psychosis

Acadia Pharmaceuticals, a renowned US-based biopharmaceutical company dedicated to the development of treatments for central nervous system disorders, reportedly announced positive outcomes from its Phase 3 HARMONY study of pimavanserin.

The company announced these positive outcomes during the 12th CTAD (Clinical Trials on Alzheimer’s Disease) meeting being held in San Diego, California between December 4 and 7, 2019.

HARMONY was a relapse prevention, double-blind, placebo-controlled trial in 392 patients for the evaluation of pimavanserin to treat dementia-related psychosis.

Director Emeritus of Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Jeffrey Cummings, M.D., Sc.D. stated that the outcomes showcased are a crucial advancement for caregivers and patients who struggle with the weight of dementia-related psychosis, a niche where there is no FDA-approved therapy currently available.  

Cummings further added that decreasing the threat of relapse of psychotic symptoms with this margin is a vital and meaningful result. This is because these are very serious events that could further lead to poor patient results and substantial growth in caregiver distress and burden.

The Phase 3 HARMONY trial comprised a 12-week open-label pimavanserin therapy period before the randomization period of the trial. During this open-label therapy period, 61.8% of eligible patients were able to reach to pre-specified criteria for pimavanserin therapy response at week 12 and week 8 both.

For patients in the open-label therapy period, alteration from baseline to week 8 and then to week 12 on the SAPS-H+D (Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions) score increased by 63.0% as well as 75.2% respectively.

President of ACADIA, Serge Stankovic, M.D., M.S.P.H., stated that the company is thrilled to unveil the top-line outcomes from this Phase 3 study to treat dementia-related psychosis. The HARMONY trial was innovated to get solutions for three very important problems. First, during the 12-week open-label period, treatment through pimavanserin indicated a meaningful decrease of the symptoms. Also, a reduction in the stabilization of psychosis through all the five clinically detected subtypes evaluated were seen.

Second, during the 26-week double-blind timeframe, patients dosed with pimavanserin had an almost three-fold decrease in risk of relapse in comparison with patients on placebo. Third, elderly patients suffering from dementia-related psychosis could tolerate pimavanserin well.

The company looks forward to discussing these outcomes with the FDA in the first half of the coming year.

 

 

Source credit: https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-presents-positive-top-line-results?field_nir_news_date_value%5bmin%5d=



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Inzomelid declares positive CAPS treatment results, completes Phase I
Inzomelid declares positive CAPS treatment results, completes Phase I
By Pankaj Singh

Inflammasome biotech company Inflazome has reportedly announced the successful completion of Inzomelid’s Phase I clinical study. In addition, the firm has also declared that it has observed positive results from ...

Flipkart to re-open its online portal to deliver essential products
Flipkart to re-open its online portal to deliver essential products
By Pankaj Singh

Flipkart, a renowned Indian e-commerce company, reportedly announced that it would be re-starting its online portal to deliver essential commodities across India. The company had closed down all its operations on Wedne...

American Furniture Warehouse to offer engaging digital receipts
American Furniture Warehouse to offer engaging digital receipts
By Pankaj Singh

American Furniture Warehouse, one of the leading furniture retail firms in the U.S, has reportedly selected flexEngage, a prominent player in personalized transactional communications, for offering dynamic digital rece...